Anlon Healthcare announces a new order win

The total committed cash outlay for the capacity expansion through inorganic acquisitions is Rs 49.19 Crores, comprising Rs 25.40 Crores for a 67.48% stake in Apiqo Organics Pvt. Ltd. and Rs 23.79 Crores for a 56.67% stake in Bizotic Lifescience Pvt. Ltd ^[1].

Timeline and Commercialization

• Apiqo Organics: Acquisition has already been completed, bringing an incremental capacity of 700–800 MTPA ^[1].
• Bizotic Lifescience: The Share Purchase Agreement (SPA) has been executed, with transaction completion expected within approximately 3 months, adding an incremental capacity of 300–400 MTPA ^[1].
• Capacity Target: Combined installed capacity across Anlon (400 MTPA) and the two acquired entities is projected to reach 1,400–1,600 MTPA by FY26, supporting the company's guidance of ~30% revenue CAGR over the next three years ^[1].

Anlon Healthcare Limited's (AHCL) announced strategic acquisitions and capacity expansion will moderately increase its net debt-to-equity ratio from 0.17x to a pro-forma level of approximately 0.38x, while operational EBITDA expansion from a 3.5x–4.0x capacity increase is expected to prevent severe deterioration in interest coverage.

---

Acquisition Outlay and Capacity Scaling Overview

AHCL announced two all-cash strategic acquisitions in Q1 FY27 to scale its manufacturing infrastructure and fast-track product diversification without relying solely on greenfield timelines ^[1].

• Notes: † Cash consideration total is derived from Rs 25.40 Crores ^[1] and Rs 23.79 Crores ^[1]. Incremental capacity total is derived from individual asset ranges ^[1].*

---

Balance Sheet Impact & Leverage Trajectory

The total cash consideration of Rs 49.19 Crores required for the acquisitions exceeds AHCL’s baseline consolidated cash and cash equivalents of Rs 4.37 Crores as of Q4 FY26 ^[2]. Assuming the funding gap is financed predominantly through debt, the company's leverage ratio will adjust as follows:

• Notes: † Pro-forma figures are derived by adding the Rs 49.19 Crores acquisition outlay ^[1] to reported Q4 FY26 baseline debt metrics ^[4], holding base consolidated equity constant at Rs 230.23 Crores ^[5].*
• Leverage Shift: The net debt-to-equity ratio shifts from a low baseline of 0.17x ^[6] to ~0.38x. Despite the increase, total leverage remains well within conservative thresholds (<0.50x), leaving adequate balance sheet headroom for operational working capital.
• Standalone Baseline: On a standalone basis, AHCL entered Q1 FY27 with Net Debt of Rs 42.19 Crores ^[7] and Total Equity of Rs 209.77 Crores ^[8], yielding a standalone net debt-to-equity ratio of 0.20x ^[9].

---

Interest Coverage Trajectory & Earnings Offset

AHCL’s consolidated interest coverage ratio stood at a strong 26.84x at the close of Q4 FY26 ^[10] (standalone interest coverage: 11.80x ^[11]).

While the added debt burden will raise absolute annual interest expense, the interest coverage ratio is expected to be supported by incoming operational earnings:

• EBITDA Expansion: Total manufacturing capacity scales 3.5x–4.0x from 400 MTPA to 1,400–1,600 MTPA ^[1]. Management targets a sustainable consolidated EBITDA margin of ~25% ^[12], supported by backward integration benefits from Apiqo and Bizotic ^[1], ^[12].
• Revenue Growth Guidance: The expanded capacity underpins guidance of ~30% revenue CAGR over the next 3 years ^[1], ^[12], alongside the planned launch of 7 new APIs in FY27 ^[12].
• Coverage Outlook: Higher operating cash flow and expanded EBITDA should absorb the higher debt servicing costs, keeping projected interest coverage comfortable, although below the peak pre-acquisition baseline of 26.84x ^[10].

---

Key Execution Risks and Disclosure Gaps

• Funding Structure Details: Specific loan terms, interest rates, and the exact split between debt borrowings and internal cash accruals for the Rs 49.19 Crores acquisition outlay ^[1] were not explicitly disclosed in the presentation.
• Working Capital Intensity: Ramping up integrated capacity across Apiqo and Bizotic from 400 MTPA to up to 1,600 MTPA ^[1] will require additional short-term working capital borrowings, which could incrementally add to gross debt.
• Completion Timelines: While the Apiqo acquisition is completed ^[1], the Bizotic transaction SPA is executed with completion expected within ~3 months ^[1]. Any delay in integration could temporarily depress short-term return ratios (Q4 FY26 consolidated ROCE: 5.6% ^[13]; ROE: 4.8% ^[14]).